top of page
News
Chat
Analysis
Education
About
Pricing
BPIQ API
BPIQ Blog
Mar 14, 2019
1 min read
UROV's Vibegron Imminent Phase 3 Readout In Overactive Bladder Has a Good Chance of Success
Based on robust Ph2B and Ph3 (Japan) data in prior trials with similar design, it appears highly likely that UROV's Vibegron will meet...
Jump start your biotech due diligence
Get started →
Our platform helps you uncover your next biotech investment opportunity
bottom of page
